Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression
Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter
Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter
View: Text | PDF
Research Article Cell biology Immunology Oncology

ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression

  • Text
  • PDF
Abstract

Our research uncovers a role for ATR in responding to ECM stiffness and promoting epithelial-to-mesenchymal transition (EMT) and metastasis. ATR, when deubiquitinated and upregulated by USP21 under enhanced ECM stiffness conditions, phosphorylates the nuclear protein SUN2, which promotes β-catenin nuclear translocation and EMT. ATM-mediated EMT promotes polymorphonuclear myeloid-derived suppressor cell recruitment and inhibits CD103+ dendritic cells, fostering an immunosuppressive tumor milieu. ATR inhibition disrupts this malignant cascade by promoting mesenchymal-to-epithelial transition to enhance antitumor immunity and mitigate metastases. Consistently, circulating HLA-DR+ dendritic cells were also enhanced following treatment with the ATR inhibitor berzosertib in patients with therapeutically resistant early-stage breast cancer. Our data suggest that ATR-targeted therapy may be optimized by considering both DNA damage–dependent and EMT-inducing effects of ATR

Authors

Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter

×

Figure 5

ATR induces EMT by phosphorylating SUN2.

Options: View larger image (or click on image) Download as PowerPoint
ATR induces EMT by phosphorylating SUN2.
(A and B) ATR phosphorylates SU...
(A and B) ATR phosphorylates SUN2 at S12. MDA-MB-231 cells expressing empty vector, FLAG-SUN2 WT, or FLAG-SUN2 S12A were subjected to FLAG immunoprecipitation, followed by immunoblotting with a phospho-(Ser/Thr) ATM/ATR substrate antibody. Quantification was performed using a 2-tailed Student’s t test (n = 3). (C and D) Matrix stiffness promotes SUN2 phosphorylation. Cells expressing empty vector or FLAG-SUN2 WT were cultured on substrates of different stiffnesses for 24 hours, followed by FLAG immunoprecipitation and SUN2 phosphorylation analysis. Statistical significance was determined using 2-tailed Student’s t test (n = 3). (E–H) ATR inhibition or knockdown suppresses stiffness-induced SUN2 phosphorylation. SUN2-overexpressing cells cultured on substrates of different stiffnesses were treated with DMSO or VX970 for 18 hours (E and F) or infected with control or ATR-targeting shRNA (G and H). SUN2 phosphorylation was assessed following FLAG or SUN2 immunoprecipitation. Data were analyzed by 2-way ANOVA (n = 3). (I and J) SUN2 S12 phosphorylation is required for MDA-MB-231 invasion. Control, SUN2-knockdown, and SUN2-knockdown cells reconstituted with SUN2 WT or S12A were cultured for 3 days on collagen type I gels of different stiffnesses (150 Pa and 1 kPa). Invasion depth was measured by DAPI staining and analyzed by 2-way ANOVA (n = 3). (K and L) SUN2 knockdown decreases N-cadherin and increases E-cadherin expression. Protein levels were assessed by immunoblotting and analyzed by 2-way ANOVA (n = 3). (M and N) Reexpression of SUN2 WT, but not S12A, rescues the changes in E- and N-cadherin caused by SUN2 knockdown. Quantification was performed using 2-way ANOVA (n = 3). Data are presented as mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts